Product Program year 2025 Source: CMS Open Payments

Aranesp

Biological Nephrology

NDC 55513-025-04

Open in the dashboard

General payments

$156,044

2,581 payments

Research payments

$477,601

19 payments

Through program year 2025, $156,044 in general payments and $477,601 in research payments were reported against Aranesp (Nephrology).

No combined total These are different kinds of money, reported under different rules. A meal and a clinical trial grant do not add up to anything meaningful, so this site does not add them.

By program year

11 rows
Year Kind Amount Payments
2025 General $774 16
2024 General $53,750 1,706
2024 Research $3,311 3
2023 General $19,442 552
2022 General $13,547 88
2021 General $12,640 17
2021 Research $807 3
2020 General $2,517 2
2020 Research $187,875 1
2019 General $53,373 200
2019 Research $285,607 12

Breakdown

Who paid General payments · program years 2019–2025
  1. Amgen Inc. $156,044 2,581 payments
Top recipients General payments · program year 2025
  1. Anjay Rastogi Nephrology · Los Angeles, CA $175 23% · 2 payments
  2. Robert Toto Nephrology · Dallas, TX $133 17% · 1 payment
  3. Maple Fung Nephrology · San Diego, CA $133 17% · 1 payment
  4. Edward Fisher Nephrology · Charlotte, NC $109 14% · 2 payments
  5. Neil Kumar Nephrology · Roseburg, OR $54 7% · 2 payments

The top 5 of 13 recipients; each share is of general payments naming this product in 2025.

The top 25 recipients, free in the app

Specialties paid General payments · program year 2025
  1. Nephrology Internal Medicine $737 95% · 11 practitioners
  2. Physician Assistant $23 3% · 1 practitioner
  3. Hospitalist $14 2% · 1 practitioner

Each share is of general payments naming this product to practitioners with a specialty in 2025. Each practitioner is counted under their primary specialty.

Where the money went General payments · program year 2025
  1. California $323 42% · 3 recipients
  2. Texas $183 24% · 3 recipients
  3. North Carolina $109 14% · 1 recipient
  4. Georgia $60 8% · 3 recipients
  5. Oregon $54 7% · 1 recipient

The top 5 of 6 states; each share is of general payments naming this product in 2025 where a state was reported.

The top 25 states, free in the app

Prescribed to Medicare patients

Part D · data year 2024

Part D claims

18,619

Prescriptions dispensed, refills included

Drug cost

$47,271,139

Paid at the pharmacy, in all

Prescribers

462

With 11 or more claims of it

Medicare Part D drugs matched to Aranesp, 2024
Part D drug Name match Relative to the largest Prescribers Claims Drug cost
Aranesp Darbepoetin Alfa In Polysorbat Same name 462 18,619 $47,271,139

Matched to this product by name; CMS does not link its files to Open Payments, so a similar name can be a different strength, form or brand. Prescriber counts include only prescribers with 11 or more claims of the drug, because CMS publishes nothing below that. Part D covers drugs dispensed to Medicare beneficiaries at a pharmacy; it does not include drugs given in a clinic or hospital, or patients with other insurance.

Largest prescribers

First 5 of 100 by claims · 2024

Two separate records. Claims come from Medicare and related payments from Open Payments. They are shown in one row because they name the same product; they do not show that a payment affected a prescription.

The prescribers with the most Part D claims of this drug in 2024
Prescriber Specialty State Claims Drug cost Related payments
Deepali Sharma Internal Medicine NY 367 $1,347,545 None on record
Alexander Zuhoski Medical Oncology NY 354 $1,325,959 None on record
Louis Avvento Medical Oncology NY 297 $1,066,784 None on record
Edward Lee Internal Medicine NY 268 $325,795 None on record
Noshir Dacosta Medical Oncology NY 250 $833,512 None on record

"No profile" means the prescriber has no Open Payments record here; "None on record" means no payment naming this product in the payment year. Related payments are general payments, and one that names several products is split evenly, so an amount is payments related to the product, not money paid for it. The list is the prescribers with the most claims, up to 100 per drug.

See more in the dashboard: 25 with a free account, all 100 with Patron

Given in the clinic

Part B · billing code
Medicare Part B billing codes matched to Aranesp
Billing code Providers Services Paid by Medicare
Injection, darbepoetin alfa, 1 microgram (non-esrd use) J0881 1,179 20,179,038 $46,586,042

Drugs given by a clinician are billed to Medicare Part B, not Part D. The product is tied to a billing code through the NDC on CMS's crosswalk, which was published for a later quarter than the payments, so a code that changed in between can be missed. Providers with fewer than 11 patients for the code are not published. Medicare's payment here is what it paid for the services, to the billing practice.

2,581 general · 19 research

Every payment, record by record

Date, amount, who was paid and what for — filter by year and kind, or download as CSV, free, in files of 5,000 rows.

What you are looking at

Manufacturers name the drug, biological or device a payment relates to. CMS does not give products their own identifiers, so a product here is assembled from how it was reported — a brand may appear under more than one spelling, and this page covers one of them rather than the brand as a whole.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record